Custom Manufacturing, Project Outsourcing, your Trusted Partner from China
The journey of a new drug from laboratory discovery to clinical application is a rigorous process, and Deucravacitinib has navigated this path with impressive results. Extensive clinical trials have been pivotal in establishing its efficacy and safety profile for the treatment of moderate to severe plaque psoriasis, as well as exploring its potential in other autoimmune diseases.
The cornerstone of Deucravacitinib's approval lies in the robust data generated from Phase 3 clinical trials, notably the POETYK PSO-1 and POETYK PSO-2 studies. These landmark trials were designed to directly compare Deucravacitinib's performance against placebo and apremilast, a well-established oral treatment. The results consistently showed that a significant proportion of patients treated with Deucravacitinib achieved substantial improvements in skin clearance, as measured by the Psoriasis Area and Severity Index (PASI) score and the static Physician's Global Assessment (sPGA). Specifically, patients receiving Deucravacitinib demonstrated superior outcomes at week 16 and maintained these benefits through week 52, highlighting its durability.
Furthermore, Deucravacitinib clinical trials have focused on its safety and tolerability. The trials indicated a favorable safety profile, with common side effects including nasopharyngitis and upper respiratory tract infections. More serious adverse events, such as severe infections or malignancies, were monitored closely and found to be at rates comparable to or lower than those seen with other immunosuppressive therapies, especially considering its targeted mechanism. The drug's oral administration also contributes to a better patient experience compared to injectable treatments.
Beyond psoriasis, Deucravacitinib is being investigated in several other Phase 3 trials for conditions such as psoriatic arthritis, Crohn's disease, lupus nephritis, and systemic lupus erythematosus. These ongoing studies aim to leverage Deucravacitinib's ability to modulate key inflammatory pathways in a broader range of autoimmune disorders. The consistent positive outcomes across various trial phases provide strong evidence for Deucravacitinib's therapeutic potential and its role as a valuable new treatment option for patients suffering from immune-mediated diseases.
Manufacturing Facilities
Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.
